Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.35 |
| ▸ | MAOB | P27338 | 4/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.34 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.34 |
| ▸ | PPARD | Q03181 | 3/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SOD1 | P00441 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6302039 | 0.94 | LTB4R (0.35) | MAOAMAOBLTB4RLTB4R2BRD4 | |
| SCHEMBL6307052 | 0.93 | BRD4 (0.37) | MAOAMAOBLTB4RLTB4R2BRD4 | |
| SCHEMBL6307914 | 0.92 | PPARD (0.34) | MAOAMAOBLTB4RLTB4R2PPARD | |
| SCHEMBL6300976 | 0.92 | MAOA (0.34) | MAOAMAOBLTB4RLTB4R2PPARD | |
| SCHEMBL6306046 | 0.92 | BRD4 (0.35) | MAOAMAOBLTB4RLTB4R2BRD4 | |
| SCHEMBL6299516 | 0.92 | MAOA (0.37) | MAOAMAOBLTB4RLTB4R2BRD4 | |
| SCHEMBL6300104 | 0.91 | MAOA (0.35) | MAOAMAOBLTB4RLTB4R2PPARD | |
| SCHEMBL6301748 | 0.91 | MAOA (0.37) | MAOAMAOBLTB4RLTB4R2BRD4 | |
| SCHEMBL6307756 | 0.91 | MAOA (0.36) | MAOAMAOBLTB4RLTB4R2BRD4 | |
| SCHEMBL6299535 | 0.91 | MAOA (0.36) | MAOAMAOBLTB4RLTB4R2PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | WARNER-LAMBERT COMPANY | 2004-03-04 | — | — | US | claimed |
| US-6943183-B2 | 5-substituted tetralones as inhibitors of ras farnesyl transferase | PFIZER INC (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | WARNER-LAMBERT COMPANY | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | PTAR1, FNTA, GGPS1 | MAOA 3197/4885MAOB 2947/4885LTB4R 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.